Immune checkpoint inhibitors for AML: mechanism, rationale & using azacitidine to boost response
Checkpoint inhibitors: parallel management of the disease and immune-related toxicities
Advances in AML understanding: APL therapy, immunotherapy and maintenance therapy
Alan Burnett et al.
Results of CheckMate 039 trial of nivolumab in combination with ipilimumab for Hodgkin lymphoma
Nivolumab in combination with azacitidine in patients with relapsed acute myeloid leukemia (AML)